Achieve announces completion of target enrollment of 750 subjects in phase 3 orca-2 smoking cessation trial of cytisinicline

Orca-2 designed to assess the efficacy and safety of 3 mg cytisinicline three times daily dosing compared to placebo in adult smokers in the united states seattle, wa and vancouver, bc / accesswire / june 29, 2021 / achieve life sciences, inc. (nasdaq:achv), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that the phase 3 orca-2 trial of cytisinicline has reached its enrollment target of 750 adult smokers. the orca-2 trial sites are no longer enrolling new subjects, however those currently in screening will be allowed to participate provided they meet entry criteria.
ACHV Ratings Summary
ACHV Quant Ranking